146 related articles for article (PubMed ID: 38691860)
1. Unraveling molecular advancements in chordoma tumorigenesis and treatment response: a review of scientific discoveries and clinical implications.
Jin MC; Connolly ID; Ravi K; Tobert DG; MacDonald SM; Shin JH
Neurosurg Focus; 2024 May; 56(5):E18. PubMed ID: 38691860
[TBL] [Abstract][Full Text] [Related]
2. Emerging Therapeutic Targets in Chordomas: A Review of the Literature in the Genomic Era.
Gill CM; Fowkes M; Shrivastava RK
Neurosurgery; 2020 Feb; 86(2):E118-E123. PubMed ID: 31504814
[TBL] [Abstract][Full Text] [Related]
3. Novel therapeutic targets in chordoma.
Bydon M; Papadimitriou K; Witham T; Wolinsky JP; Bydon A; Sciubba D; Gokaslan Z
Expert Opin Ther Targets; 2012 Nov; 16(11):1139-43. PubMed ID: 22860993
[TBL] [Abstract][Full Text] [Related]
4. [Chordoma].
George B; Bresson D; Bouazza S; Froelich S; Mandonnet E; Hamdi S; Orabi M; Polivka M; Cazorla A; Adle-Biassette H; Guichard JP; Duet M; Gayat E; Vallée F; Canova CH; Riet F; Bolle S; Calugaru V; Dendale R; Mazeron JJ; Feuvret L; Boissier E; Vignot S; Puget S; Sainte-Rose C; Beccaria K
Neurochirurgie; 2014 Jun; 60(3):63-140. PubMed ID: 24856008
[TBL] [Abstract][Full Text] [Related]
5. Molecular and clinical risk factors for recurrence of skull base chordomas: gain on chromosome 2p, expression of brachyury, and lack of irradiation negatively correlate with patient prognosis.
Kitamura Y; Sasaki H; Kimura T; Miwa T; Takahashi S; Kawase T; Yoshida K
J Neuropathol Exp Neurol; 2013 Sep; 72(9):816-23. PubMed ID: 23965741
[TBL] [Abstract][Full Text] [Related]
6. From notochord formation to hereditary chordoma: the many roles of Brachyury.
Nibu Y; José-Edwards DS; Di Gregorio A
Biomed Res Int; 2013; 2013():826435. PubMed ID: 23662285
[TBL] [Abstract][Full Text] [Related]
7. T gene isoform expression pattern is significantly different between chordomas and notochords.
Wang K; Hu Q; Wang L; Chen W; Tian K; Cao C; Wu Z; Jia G; Zhang L; Zeng C; Zhang J
Biochem Biophys Res Commun; 2015 Nov; 467(2):261-7. PubMed ID: 26435504
[TBL] [Abstract][Full Text] [Related]
8. Clinical findings in families with chordoma with and without T gene duplications and in patients with sporadic chordoma reported to the Surveillance, Epidemiology, and End Results program.
Parry DM; McMaster ML; Liebsch NJ; Patronas NJ; Quezado MM; Zametkin D; Yang XR; Goldstein AM
J Neurosurg; 2020 Jun; 134(5):1399-1408. PubMed ID: 32559743
[TBL] [Abstract][Full Text] [Related]
9. Genomic and transcriptomic characterization of skull base chordoma.
Sa JK; Lee IH; Hong SD; Kong DS; Nam DH
Oncotarget; 2017 Jan; 8(1):1321-1328. PubMed ID: 27901492
[TBL] [Abstract][Full Text] [Related]
10. Notochordal Tumors: An Update on Molecular Pathology with Therapeutic Implications.
Yamaguchi T; Imada H; Iida S; Szuhai K
Surg Pathol Clin; 2017 Sep; 10(3):637-656. PubMed ID: 28797506
[TBL] [Abstract][Full Text] [Related]
11. The molecular aspects of chordoma.
Gulluoglu S; Turksoy O; Kuskucu A; Ture U; Bayrak OF
Neurosurg Rev; 2016 Apr; 39(2):185-96; discussion 196. PubMed ID: 26363792
[TBL] [Abstract][Full Text] [Related]
12. Genetic aberrations and molecular biology of skull base chordoma and chondrosarcoma.
Kitamura Y; Sasaki H; Yoshida K
Brain Tumor Pathol; 2017 Apr; 34(2):78-90. PubMed ID: 28432450
[TBL] [Abstract][Full Text] [Related]
13. The role of systemic therapy in advanced skull base chordomas: overview of the current state and the MD Anderson protocol.
Banu MA; Raza SM; Amini M; Seaman S; Rubino F; Snyder R; Patel S; DeMonte F; Conley AP
Neurosurg Focus; 2024 May; 56(5):E15. PubMed ID: 38691867
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical markers predicting long-term recurrence following clival and spinal chordoma resection: a multicenter study.
Ghaith AK; Akinduro OO; Alexander AY; Goyal A; Bon-Nieves A; de Macedo Filho L; Otamendi-Lopez A; Nathani KR; Abode-Iyamah K; Jentoft ME; Bendok BR; Clarke MJ; Link MJ; Van Gompel JJ; Quiñones-Hinojosa A; Bydon M
Neurosurg Focus; 2023 Jun; 54(6):E15. PubMed ID: 37552641
[TBL] [Abstract][Full Text] [Related]
15. Brachyury gene copy number gain and activation of the PI3K/Akt pathway: association with upregulation of oncogenic Brachyury expression in skull base chordoma.
Otani R; Mukasa A; Shin M; Omata M; Takayanagi S; Tanaka S; Ueki K; Saito N
J Neurosurg; 2018 May; 128(5):1428-1437. PubMed ID: 28753115
[TBL] [Abstract][Full Text] [Related]
16. High-resolution whole-genome analysis of skull base chordomas implicates FHIT loss in chordoma pathogenesis.
Diaz RJ; Guduk M; Romagnuolo R; Smith CA; Northcott P; Shih D; Berisha F; Flanagan A; Munoz DG; Cusimano MD; Pamir MN; Rutka JT
Neoplasia; 2012 Sep; 14(9):788-98. PubMed ID: 23019410
[TBL] [Abstract][Full Text] [Related]
17. Skull base chordomas review of current treatment paradigms.
Yaniv D; Soudry E; Strenov Y; Cohen MA; Mizrachi A
World J Otorhinolaryngol Head Neck Surg; 2020 Jun; 6(2):125-131. PubMed ID: 32596658
[TBL] [Abstract][Full Text] [Related]
18. Contemporary management of clival chordomas.
Campbell RG; Prevedello DM; Ditzel Filho L; Otto BA; Carrau RL
Curr Opin Otolaryngol Head Neck Surg; 2015 Apr; 23(2):153-61. PubMed ID: 25692630
[TBL] [Abstract][Full Text] [Related]
19. Tumor-biology and current treatment of skull-base chordomas.
Pamir MN; Ozduman K
Adv Tech Stand Neurosurg; 2008; 33():35-129. PubMed ID: 18383812
[TBL] [Abstract][Full Text] [Related]
20. Current therapeutic options and novel molecular markers in skull base chordomas.
Gagliardi F; Boari N; Riva P; Mortini P
Neurosurg Rev; 2012 Jan; 35(1):1-13; discussion 13-4. PubMed ID: 22006091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
